

22102144D

SENATE BILL NO. 376

Offered January 12, 2022

Prefiled January 11, 2022

A *BILL to amend the Code of Virginia by adding in Chapter 34 of Title 38.2 an article numbered 10, consisting of sections 38.2-3471 through 38.2-3480, relating to Prescription Drug Affordability Board established; drug cost affordability review.*

Patrons—Petersen, Bell, Ebbin and Spruill

Referred to Committee on Education and Health

Be it enacted by the General Assembly of Virginia:

1. That the Code of Virginia is amended by adding in Chapter 34 of Title 38.2 an article numbered 10, consisting of sections numbered 38.2-3471 through 38.2-3480, as follows:

§ 38.2-3471. Definitions.

As used in this article, unless the context requires a different meaning:

"*Biologic*" means a drug that is produced or distributed in accordance with a biologics license application approved under 42 C.F.R. § 447.502.

"*Biosimilar*" means a drug that is produced or distributed in accordance with a biologics license application approved under 42 C.F.R. § 262(K)(3).

"*Board*" means the Prescription Drug Affordability Board.

"*Brand-name drug*" means a drug that is produced or distributed in accordance with an original new drug application approved under 21 U.S.C. § 355(C). "*Brand-name drug*" does not include an authorized generic as defined by 42 C.F.R. § 447.502.

"*Drug product*" means a brand-name drug, a generic drug, a biologic or biosimilar, or an over-the-counter drug.

"*ERISA plan*" means any self-funded employee welfare benefit plan governed by the requirements of the Employee Retirement Income Security Act of 1974, 29 U.S.C. § 1002(1).

"*Generic drug*" means (i) a retail drug that is marketed or distributed in accordance with an abbreviated new drug application, approved under 21 U.S.C. § 355(J); (ii) an authorized generic as defined by 42 C.F.R. § 447.502; or (iii) a drug that entered the market before 1962 that was not originally marketed under a new drug application.

"*Manufacturer*" means an entity that (i) engages in the manufacture of a drug product or (ii) enters into a lease with another manufacturer to market and distribute a prescription drug product under the entity's own name and (iii) sets or changes the wholesale acquisition cost of the prescription drug product it manufactures or markets.

"*Prescription drug product*" means a brand-name drug, a generic drug, a biologic, or a biosimilar.

"*Stakeholder council*" means the Prescription Drug Affordability stakeholder council.

§ 38.2-3472. Prescription Drug Affordability Board.

A. There is hereby established the Prescription Drug Affordability Board for the purpose of protecting state residents, particularly patients experiencing physical and mental illnesses and communities affected by the opioid crisis; state and local governments; commercial health plans; health care providers; pharmacies licensed in the Commonwealth; and other stakeholders within the health care system from the high costs of prescription drug products.

B. The Board shall be composed of five members to be appointed by the Governor and confirmed by the Senate and House of Delegates. The Governor may appoint three alternate members of the Board who shall likewise be confirmed by the Senate and House of Delegates prior to assuming a position on the Board. Members of the board shall have expertise in health care, health care economics, or clinical medicine. A member or alternate member may not be an employee of, a board member of, or a consultant to a manufacturer or trade association for manufacturers. Any conflict of interest, including whether an individual has an association, including a financial or personal association, that has the potential to bias or has the appearance of biasing the individual's decisions in matters related to the Board or the conduct of the Board's activities shall be disclosed and considered when appointing members and alternate members to the Board.

C. The term of a member or alternate member of the Board shall be five years. The terms of the members and alternate members shall be staggered as required by the provisions for members in § 38.2-3479.

D. The chair of the Board shall hire an executive director, general counsel, and staff to support the board's activities. Staff of the Board shall receive a salary as provided in the budget of the Board. A

INTRODUCED

SB376

59 member of the board may receive compensation as a member of the board in accordance with the state
60 budget and is entitled to reimbursement for expenses under standard state travel regulations as provided
61 in the state budget.

62 E. A majority of the members of the Board shall constitute a quorum for the purposes of conducting
63 the business of the Board.

64 F. Subject to subdivision 2, the Board shall meet in open session at least four times annually to
65 review prescription drug product information. The following provisions shall also apply to meetings of
66 the Board:

67 1. The chair may cancel or postpone a meeting if there is no business to transact.

68 2. The following actions by the Board shall be made in open session: (i) deliberations on whether to
69 subject a prescription drug product to an affordability review under § 38.2-3475, (ii) any vote on
70 whether to impose an upper payment limit on purchases and payer reimbursements of prescription drug
71 products in the Commonwealth, and (iii) any significant decision by the Board.

72 3. The Board may meet in closed session to discuss proprietary data and information.

73 4. The Board shall provide public notice of each board meeting at least two weeks in advance of the
74 meeting.

75 5. Materials for each meeting shall be made available to the public at least one week in advance of
76 the meeting.

77 6. The Board shall provide an opportunity for public comment at each open meeting of the Board.

78 7. The Board shall provide the public with the opportunity to provide written comments on pending
79 decisions of the Board.

80 8. The Board may allow expert testimony at its meetings, including when the Board meets in closed
81 session.

82 G. Members of the Board shall recuse themselves from decisions related to prescription drug
83 products if the member, or an immediate family member of the member, has received or could receive
84 either of the following:

85 1. A direct financial benefit of any amount deriving from the result or finding of a study or
86 determination by or for the Board; or

87 2. A financial benefit from any person that owns, manufactures, or provides prescription drug
88 products, services, or items to be studied by the Board that in the aggregate exceeds \$5,000 per year.

89 For the purposes of subdivision 1, a financial benefit includes honoraria, fees, stock, the value of the
90 member's or immediate family member's stock holdings, and any direct financial benefit deriving from
91 the finding of a review conducted pursuant to this article.

92 A conflict of interest shall be disclosed (i) by the Board when hiring Board staff, (ii) by the
93 appointing authority when appointing members and alternate members to the Board and members to the
94 stakeholder council, and (iii) by the Board when a member of the Board is recused in any final decision
95 resulting from a review of a prescription drug product. A conflict of interest shall be disclosed in
96 advance of the first open meeting after the conflict is identified or within five days after the conflict is
97 identified, whichever is sooner.

98 A conflict of interest disclosed pursuant to this section shall be posted on the website of the Board
99 unless the chair of the Board recuses the member from any final decision resulting from a review of a
100 prescription drug product. Such posting shall include the type, nature, and magnitude of the interests of
101 the member involved.

102 H. Members and alternate members of the Board, Board staff, and third-party contractors may not
103 accept any gift or donation of services or property that indicates a potential conflict of interest or has
104 the appearance of biasing the work of the Board.

105 **§ 38.2-3473. Powers and duties of the Board.**

106 A. To the extent practicable, the Board shall access pricing information for prescription drug
107 products by (i) entering into a memorandum of understanding with another state to which manufacturers
108 already report pricing information, (ii) assessing spending for prescription drugs in the state, and (iii)
109 accessing other available pricing information based on state reporting and transparency requirements,
110 including prescription drug price transparency information collected and compiled by a nonprofit data
111 services organization and the Department of Health pursuant to § 32.1-23.4.

112 B. The Board may enter into a contract with a qualified, independent third party for any service
113 necessary to carry out the powers and duties of the Board. Unless permission is granted by the Board,
114 a third party hired by the Board shall not release, publish, or otherwise use any information to which
115 the third party has access under its contract with the Board.

116 C. In addition to the powers set forth in this article, the Board may promulgate regulations for the
117 implementation of this act.

118 **§ 38.2-3474. Stakeholder council.**

119 A. The Board shall create a stakeholder council for the purpose of providing stakeholder input to
120 assist the Board in making decisions as required under this article. The stakeholder council shall consist

of 19 members appointed in accordance with this section. Members shall include manufacturers of brand-name and generic prescription drugs, providers that dispense or administer prescription drugs, prescription drug suppliers, and consumers of prescription drugs. More than one council member shall not be appointed to represent any single organization or entity.

B. The President Pro Tempore of the Senate shall appoint five members, the Speaker of the House of Delegates shall appoint seven members, and the Governor shall appoint seven members to the stakeholder council.

C. The members of the stakeholder council shall have knowledge in one or more of the following subjects: (i) the pharmaceutical business model, (ii) supply chain business models, (iii) the practice of medicine or clinical training, (iv) consumer or patient perspectives, (v) health care costs trends and drivers, (vi) clinical and health services research, or (vii) the state's health care marketplace.

D. From among the membership of the stakeholder council, the Board chair shall appoint two members to be co-chairs of the stakeholder council.

E. The initial term for members of the stakeholder council shall be three years, and the members shall serve staggered terms as required by the provisions for members in § 38.2-3479.

F. A member of the stakeholder council may not receive compensation as a member of the stakeholder council but is entitled to reimbursement for expenses under standard state travel regulations as provided in the state budget.

§ 38.2-3475. Drug cost affordability review.

A. Nothing in this section shall be construed to prevent a manufacturer from marketing a prescription drug product approved by the U.S. Food and Drug Administration (FDA) while the product is under review by the Board.

B. The Board shall identify the following prescription drug products offered for sale in the Commonwealth:

1. Brand-name drugs or biologics that, as adjusted annually for inflation in accordance with the consumer price index, have (i) a launch wholesale acquisition cost of \$30,000 or more per year or course of treatment or (ii) a wholesale acquisition cost increase of \$3,000 or more in any 12-month period.

2. Biosimilar drugs that have a launch wholesale acquisition cost that is not at least 15 percent lower than the referenced brand biologic at the time the biosimilars are launched.

3. a. Generic drugs that, as adjusted for inflation in accordance with the consumer price index, have a wholesale acquisition cost of \$100 or more for (i) a 30-day supply lasting a patient for a period of 30 consecutive days based on the recommended dosage approved for labeling by the FDA, (ii) a supply lasting a patient fewer than 30 days based on the recommended dosage approved for labeling by the FDA, or (iii) one unit of the drug if the labeling approved by the FDA does not recommend any finite dosage; and

b. Generic drugs that, as adjusted for inflation in accordance with the consumer price index, have a wholesale acquisition cost that increased by 200 percent or more during the immediately preceding 12-month period, as determined by the difference between the resulting wholesale acquisition cost and the average of the wholesale acquisition cost reported over the immediately preceding 12 months.

4. Other prescription drug products that may create affordability challenges for the state health care system and patients, including drugs used to address public health emergencies.

C. After identifying prescription drug products as required by subsection B, the Board shall determine whether to conduct an affordability review for each identified prescription drug product by seeking stakeholder council input about the product and considering the average patient cost share of the product. Relevant information for conducting an affordability review may include any document or research related to the manufacturer's selection of the introductory price or price increase of the prescription drug product, including lifecycle management, net average prices in the state, market competition and context, projected revenue, and the estimated value or cost effectiveness of the prescription drug product. Failure of a manufacturer to provide the Board with relevant information for an affordability review shall not affect the Board's authority to conduct such a review.

D. An affordability review conducted by the Board pursuant to subsection C shall determine whether the prescription drug product that is fully consistent with the labeling approved by the FDA or standard medical practice has led or will lead to affordability challenges for the state health care system or high out-of-pocket costs for patients. To the extent practicable, in determining whether a prescription drug product has led or will lead to an affordability challenge, the Board shall consider the following factors:

1. The wholesale acquisition cost for the prescription drug product sold in the Commonwealth;

2. The average monetary price concession, discount, or rebate the manufacturer provides or is expected to provide to health plans in the state as reported by manufacturers and health plans, expressed as a percentage of the wholesale acquisition cost for the prescription drug product under

182 review;

183 3. The total amount of the price concession, discount, or rebate the manufacturer provides to each
184 pharmacy benefits manager operating in the state for the prescription drug product under review, as
185 reported by manufacturers and pharmacy benefits managers, expressed as a percentage of wholesale
186 acquisition costs;

187 4. The price at which therapeutic alternatives have been sold in the state;

188 5. The average monetary concession, discount, or rebate the manufacturer provides or is expected to
189 provide to health plan payers and pharmacy benefits managers in the state for therapeutic alternatives;

190 6. The cost to health plans based on patient access consistent with FDA-labeled indications and
191 recognized standard medical practice;

192 7. The impact on patient access resulting from the cost of the prescription drug product relative to
193 insurance benefit design;

194 8. The current or expected dollar value of drug-specific patient access programs that are supported
195 by the manufacturer;

196 9. The relative financial impacts to health, medical, or social services costs as can be quantified and
197 compared to baseline effects of existing therapeutic alternatives;

198 10. The average patient copay or other cost-sharing for the prescription drug product in the state;

199 11. Any information a manufacturer chooses to provide; and

200 12. Any other factors as determined by the Board through regulations adopted by the Board.

201 E. If the Board finds that the spending on a prescription drug product reviewed under this section
202 has led or will lead to an affordability challenge, the Board shall establish an upper payment limit after
203 considering the cost of administering the drug, the cost of delivering the drug to customers, and other
204 relevant administrative costs related to the drug. An upper payment limit established by the Board
205 pursuant to this subsection shall apply to all purchases and payer reimbursements of the prescription
206 drug product dispensed or administered to individuals in the Commonwealth in person, by mail, or by
207 any other means.

208 F. Any information submitted to the Board in accordance with this section shall be subject to
209 public inspection only to the extent required under the Virginia Freedom of Information Act (§ 2.2-3700
210 et seq.).

211 **§ 38.2-3476. Remedies; appeals.**

212 A. The Office of the Attorney General may pursue any appropriate available remedy under state law
213 in enforcing the provisions of this article.

214 B. Any person aggrieved by a decision of the Board may request an appeal of the decision within 30
215 days after the decision of the Board is made. The Board shall hear the appeal and make a final
216 decision within 60 days after the appeal is requested.

217 C. Any person aggrieved by a final decision of the Board may petition for judicial review as
218 provided by the Administrative Process Act (§ 2.2-4000 et seq.).

219 **§ 38.2-3477. Prescription Drug Affordability Fund.**

220 There is hereby created in the state treasury a special nonreverting fund to be known as the
221 Prescription Drug Affordability Fund, referred to in this section as "the Fund," which shall be
222 established on the books of the Comptroller. All funds appropriated for such purpose and any gifts,
223 donations, grants, bequests, and other funds received on its behalf shall be paid into the state treasury
224 and credited to the Fund. Interest earned on moneys in the Fund shall remain in the Fund and be
225 credited to it. Any moneys remaining in the Fund, including interest thereon, at the end of each fiscal
226 year shall not revert to the general fund but shall remain in the Fund. Moneys in the Fund shall be
227 used solely for the purposes of providing funding for the Board and to implement the purposes of the
228 Board established under this article, including any costs expended by any state agency in implementing
229 the provisions of this article. Expenditures and disbursements from the Fund shall be made by the State
230 Treasurer on warrants issued by the Comptroller upon written request signed by the chair of the Board.

231 **§ 38.2-3478. Reporting requirements.**

232 A. On or before December 31, 2023, and annually each year thereafter, the Board shall submit to
233 the Chair of the Senate Committee on Education and Health, the Chair of the Senate Committee on
234 Commerce and Labor, the Chair of the House Committee on Health, Welfare and Institutions, and the
235 House Committee on Labor and Commerce a report that includes the following:

236 1. Price trends for prescription drug products in the Commonwealth and nationwide;

237 2. The number of prescription drug products that were subject to Board review during the previous
238 12-month period, including the results of the reviews and the number and disposition of appeals and
239 judicial reviews of Board decisions; and

240 3. Any recommendations the Board may have regarding further legislation needed to improve
241 prescription drug affordability in the Commonwealth.

242 B. On or before July 1, 2023, the Board shall report on the operation of the generic drug market in
243 the United States, including a review of physician-administered drugs, that considers (i) the prices of

generic drugs on a year-over-year basis, (ii) the degree to which generic drug prices affect yearly insurance premium changes, (iii) annual changes in insurance cost-sharing for generic drugs, (iv) the potential for and history of drug shortages, (v) the degree to which generic drug prices affect yearly state Medicaid spending, and (vi) any other relevant study questions. The Board shall report this study to the chairs of the Senate and House committees listed in subsection A.

§ 38.2-3479. Terms of office; initial Board and stakeholder council members.

A. The terms of the initial members and alternate members of the Board shall expire as follows:

1. One member and one alternate member in 2025;
2. Two members and one alternate member in 2026; and
3. Two members, including the chair of the Board, and one alternate member in 2027.

B. The terms of the initial members of the stakeholder council shall expire as follows:

1. Five members in 2024;
2. Seven members in 2025; and
3. Seven members in 2026.

§ 38.2-3480. Relation to other health benefit plans.

The provisions of this article obligate state-sponsored and state-regulated health plans and health programs to limit drug reimbursements and drug payment amounts to no more than the Board-established upper payment limit. Plans providing health care benefits pursuant to Part D of Subchapter XVIII, Chapter 7 of Title 42 of the United States Code, known as Medicare Part D, shall not be bound by decisions of the Board and any such plans may choose to reimburse more than the upper payment limit amount. Providers who dispense and administer drugs in the state to individuals in the state shall be bound to bill all payers no more than the upper payment limit to the patient without regard to whether or not a Medicare Part D plan chooses to reimburse the provider above the upper payment limit amount.

2. That if any provision of this act or the application thereof to any person or circumstance is held invalid for any reason in a court of competent jurisdiction, the invalidity shall not affect other provisions or any other applications of this act that shall continue to be given effect without the invalid provision or application.

3. That this act shall have a delayed effective date of January 1, 2023.